Details : ATHENE study results support the benefit of NeuroAiD™II (MLC901) as a safe add-on therapy to standard AD treatment as the study found no evidence of a significant increase in adverse events between MLC901 and placebo.
Product Name : NeuroAiD II
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 21, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Seelos Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the agreement with Seelos Therapeutics, has acquired a worldwide license from iX Biopharma for Wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a technology known as Wa...
Product Name : Wafermine
Product Type : Controlled Substance
Upfront Cash : $9.0 million
November 24, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Seelos Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition